Cytosorbents Corporation announced that it expects to receive $20 million in funding
On the same date, the company received $15 million in its first tranche, with immediate availability of $10 million and an additional $5 million with the timely acceptance by U.S. FDA of the Company?s planned De Novo application for DrugSorb-ATR and certain liquidity requirements. A second tranche of $5 million would be available in the second half of 2025 with FDA marketing clearance for DrugSorb-ATM to help support an anticipated launch of the therapy in the United States.